Guggenheim notes that NCCN guidelines for prostate cancer V3.2026 were released and include updates to the principles of risk stratification and biomarkers sections. The principles of risk stratification tables include only Decipher from Veracyte (VCYT) and the MMAI test from Artera AI for intermediate risk prostate cancer and high-risk/very-high-risk prostate cancer, and only Decipher for BCR post-RP. At first look, the firm says this is an incrementally positive update for Veracyte’s Decipher as the test continues to be differentiated from other genomic classifier tests based on robust clinical evidence and inclusion in the principles of risk stratification table. Guggenheim has a Buy rating on Veracyte.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCYT:
- Veracyte Inc. Reports Robust Q3 Earnings Performance
- Veracyte rises 21.4%
- Cathie Wood Pours into Veracyte Stake ahead of Earnings Beat, Slashes Biotech Holdings
- Veracyte rises 26.4%
- Veracyte price target raised to $43 from $40 at Canaccord